De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Mangoceuticals Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jacob Cohen

Algemeen directeur

US$640.2k

Totale compensatie

Percentage CEO-salaris	40.6%
Dienstverband CEO	3yrs
Eigendom CEO	30.3%
Management gemiddelde ambtstermijn	2yrs
Gemiddelde ambtstermijn bestuur	2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Jacob Cohen's beloning veranderd ten opzichte van Mangoceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$9m
Mar 31 2024	n/a	n/a	-US$9m
Dec 31 2023	US$640k	US$260k	-US$9m
Sep 30 2023	n/a	n/a	-US$7m
Jun 30 2023	n/a	n/a	-US$6m
Mar 31 2023	n/a	n/a	-US$5m
Dec 31 2022	US$633k	US$70k	-US$2m

Compensatie versus markt: De totale vergoeding ($USD 640.24K ) Jacob } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van Jacob is gestegen terwijl het bedrijf verliesgevend is.

CEO

Jacob Cohen (45 yo)

3yrs

Tenure

US$640,238

Compensatie

Mr. Jacob D. Cohen served as an Executive Vice President of Metiscan, Inc. since joining in August 2008 until July 2011 and also served as Executive Vice President of its subsidiary, Taptopia, Inc. He is E...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jacob Cohen	Co-Founder	3yrs	US$640.24k	30.35% $ 2.2m
Eugene Johnston	Chief Financial Officer	2yrs	US$56.50k	0.67% $ 48.8k
Amanda Hammer	Chief Operating Officer	1.4yrs	US$329.43k	0.59% $ 42.7k

2.0yrs

Gemiddelde duur

45yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MGRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jacob Cohen	Co-Founder	3yrs	US$640.24k	30.35% $ 2.2m
Alexander Hamilton	Independent Director	2yrs	geen gegevens	0.084% $ 6.1k
Lorraine D'Alessio	Independent Director	2yrs	geen gegevens	0.59% $ 42.7k
Kenny Myers	Independent Director	2yrs	geen gegevens	0.59% $ 42.7k
Brian Rudman	Chairman of the Advisory Board	1.8yrs	geen gegevens	geen gegevens
Aaron Andrew	Member of Advisory Board	1.4yrs	geen gegevens	geen gegevens
Douglas Christianson	Advisory Board Member	less than a year	geen gegevens	geen gegevens

2.0yrs

Gemiddelde duur

45yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MGRX wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2 jaar), wat duidt op een nieuw bestuur.

Mangoceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Mangoceuticals, Inc.Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department

Independent Director notifies of intention to sell stock

Mangoceuticals, Inc., Annual General Meeting, Jun 17, 2024

High number of new and inexperienced directors

Mangoceuticals, Inc. Appoints Aaron Andrew to Its Advisory Board

Mangoceuticals, Inc. Appoints Amanda Hammer as New Chief Operating Officer

Recent updates

Mangoceuticals, Inc. Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions

Mangoceuticals, Inc. Launches 'Slim' Oral Semaglutide Weight Loss Treatment

Second quarter 2024 earnings released: US$0.092 loss per share (vs US$0.14 loss in 2Q 2023)

Mangoceuticals, Inc. Announces Successful Migration to Its Newly Developed DEA -Approved Telemedicine Operating System

MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via Surescripts

Mangoceuticals, Inc.Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation Department

Independent Director notifies of intention to sell stock

Mangoceuticals, Inc. Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology

Mangorx to Introduce “Mojo” Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone Imbalances

New major risk - Shareholder dilution

First quarter 2024 earnings released: US$0.10 loss per share (vs US$0.23 loss in 1Q 2023)

Mangoceuticals, Inc., Annual General Meeting, Jun 17, 2024

Mangoceuticals, Inc. Provides Non-Compliance Update

New major risk - Shareholder dilution

New major risk - Financial position

Mangoceuticals, Inc. Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex® FDA Approved Oral Testosterone Replacement Therapy Treatment

Mangoceuticals, Inc. Accepting Pre Orders for its PRIME

High number of new and inexperienced directors

Mangoceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.2 million.

Mangoceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.2 million.

Mangoceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.2 million.

Mangoceuticals, Inc. to Introduce “Prime”, Powered by Kyzatrex® (Ciii Testosterone Undecanoate Capsules), for an FDA Approved Oral Testosterone Replacement Therapy (TRT) Product

Mangoceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3.6 million.

Mangoceuticals Expands its Men's Health Product Line with Compounded Hair Growth Treatment 'Grow' by MangoRx

Mangoceuticals, Inc. Receives an Expected Letter from Listing Qualifications Department of The Nasdaq Stock Market LLC

Mangoceuticals Receives Written Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with the Minimum Bid Price Requirements Set Forth in Nasdaq Listing Rule 5550(a)(2)

New major risk - Share price stability

New major risk - Market cap size

Mangoceuticals, Inc. Launches New Sildenafil Based Erectile Dysfunction Product with Signature Mango Flavor & Rapid Dissolve

Mangoceuticals, Inc. Announces Upcoming Launch of Its Sildenafil Based Mango Flavored Rapid Dissolve ED Product

Mangoceuticals, Inc. Appoints Aaron Andrew to Its Advisory Board

Mangoceuticals, Inc. Appoints Amanda Hammer as New Chief Operating Officer

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd